These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 37696088)

  • 1. N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications.
    Wang D; Zhang Y; Li Q; Zhang A; Xu J; Li Y; Li W; Tang L; Yang F; Meng J
    Biomed Pharmacother; 2023 Nov; 167():115477. PubMed ID: 37696088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance.
    Lin H; Wang Y; Wang P; Long F; Wang T
    Mol Cancer; 2022 Jul; 21(1):148. PubMed ID: 35843942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory effects of natural products on N6-methyladenosine modification: A novel therapeutic strategy for cancer.
    Mao-Mao ; Zhang JJ; Xu YP; Shao MM; Wang MC
    Drug Discov Today; 2024 Feb; 29(2):103875. PubMed ID: 38176674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications.
    Wang L; Tang Y
    Biomed Pharmacother; 2023 Jul; 163():114846. PubMed ID: 37167725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of m6A-Mediated DNA Damage Repair in Tumor Development and Chemoradiotherapy Resistance.
    Qu L; Liu SJ; Zhang L; Liu JF; Zhou YJ; Zeng PH; Jing QC; Yin WJ
    Cancer Control; 2024; 31():10732748241247170. PubMed ID: 38662732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis.
    Chen M; Wong CM
    Mol Cancer; 2020 Feb; 19(1):44. PubMed ID: 32111216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of RNA modification N6-methyladenosine in human cancer.
    Zhou Z; Lv J; Yu H; Han J; Yang X; Feng D; Wu Q; Yuan B; Lu Q; Yang H
    Mol Cancer; 2020 Jun; 19(1):104. PubMed ID: 32513173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Writers, readers, and erasers RNA modifications and drug resistance in cancer.
    Chen D; Gu X; Nurzat Y; Xu L; Li X; Wu L; Jiao H; Gao P; Zhu X; Yan D; Li S; Xue C
    Mol Cancer; 2024 Aug; 23(1):178. PubMed ID: 39215288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N6-methyladenosine functions and its role in skin cancer.
    Ran Y; Yan Z; Jiang B; Liang P
    Exp Dermatol; 2023 Jan; 32(1):4-12. PubMed ID: 36314059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications.
    Qin S; Mao Y; Wang H; Duan Y; Zhao L
    Int J Biol Sci; 2021; 17(11):2718-2736. PubMed ID: 34345203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-methyladenosine RNA modifications: a potential therapeutic target for AML.
    Hu R; Liao P; Xu B; Qiu Y; Zhang H; Li Y
    Ann Hematol; 2024 Aug; 103(8):2601-2612. PubMed ID: 37548690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in crosstalk between N6-methyladenosine (m6A) modification and circular RNAs in cancer.
    Huang X; Guo H; Wang L; Yang L; Shao Z; Zhang W
    Mol Ther Nucleic Acids; 2022 Mar; 27():947-955. PubMed ID: 35211355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functions of N6-methyladenosine and its role in cancer.
    He L; Li H; Wu A; Peng Y; Shu G; Yin G
    Mol Cancer; 2019 Dec; 18(1):176. PubMed ID: 31801551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into the interaction between m6A modification and lncRNA in cancer drug resistance.
    Jin Y; Fan Z
    Cell Prolif; 2024 Apr; 57(4):e13578. PubMed ID: 37961996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interplay between m6A RNA methylation and noncoding RNA in cancer.
    Ma S; Chen C; Ji X; Liu J; Zhou Q; Wang G; Yuan W; Kan Q; Sun Z
    J Hematol Oncol; 2019 Nov; 12(1):121. PubMed ID: 31757221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-methyladenosine RNA modification in cancer therapeutic resistance: Current status and perspectives.
    Xu Z; Peng B; Cai Y; Wu G; Huang J; Gao M; Guo G; Zeng S; Gong Z; Yan Y
    Biochem Pharmacol; 2020 Dec; 182():114258. PubMed ID: 33017575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N6-methyladenosine methyltransferases: functions, regulation, and clinical potential.
    Huang W; Chen TQ; Fang K; Zeng ZC; Ye H; Chen YQ
    J Hematol Oncol; 2021 Jul; 14(1):117. PubMed ID: 34315512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. m6A modification: recent advances, anticancer targeted drug discovery and beyond.
    Deng LJ; Deng WQ; Fan SR; Chen MF; Qi M; Lyu WY; Qi Q; Tiwari AK; Chen JX; Zhang DM; Chen ZS
    Mol Cancer; 2022 Feb; 21(1):52. PubMed ID: 35164788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physio-pathological effects of N6-methyladenosine and its therapeutic implications in leukemia.
    Liu WW; Wang H; Zhu XY
    Biomark Res; 2022 Aug; 10(1):64. PubMed ID: 35999621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of RNA N6-methyladenosine in Cancer progression.
    Wang T; Kong S; Tao M; Ju S
    Mol Cancer; 2020 May; 19(1):88. PubMed ID: 32398132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.